open access publication

Article, Early Access, 2024

Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial

ARTHRITIS & RHEUMATOLOGY, ISSN 2326-5191, 2326-5191, 10.1002/art.42730

Contributors

Lend, K. 0000-0001-5037-5546 (Corresponding author) [1] [2] Koopman, Frieda A. [1] Lampa, J. [2] [3] Jansen, Gerrit [4] Hetland, Merete Lund [5] [6] Uhlig, Till [7] [8] Nordstroem, Dan [9] [10] Nurmohamed, Michael [1] [4] Gudbjornsson, Bjorn [11] [12] Rudin, A. [13] [14] Ostergaard, M. 0000-0003-3690-467X [5] [6] Heiberg, Marte S. [8] Sokka-Isler, T. [15] [16] Horslev-Petersen, K. [17] Haavardsholm, Espen A. [8] Grondal, G. [11] [12] Twisk, Jos [1] van Vollenhoven, Ronald 0000-0001-6438-8663 [1] [2]

Affiliations

  1. [1] Amsterdam Univ Med Ctr, Amsterdam, Netherlands
    2. [NORA names: Netherlands; Europe, EU; OECD];
  2. [2] Karolinska Inst, Stockholm, Sweden
    3. [NORA names: Sweden; Europe, EU; Nordic; OECD];
  3. [3] Karolinska Univ Hosp, Stockholm, Sweden
    4. [NORA names: Sweden; Europe, EU; Nordic; OECD];
  4. [4] Amsterdam Univ Med Ctr, Vrije Univ, Amsterdam, Netherlands
    5. [NORA names: Netherlands; Europe, EU; OECD];
  5. [5] Copenhagen Univ Hosp, Rigshosp, Glostrup, Denmark
    6. [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];

Abstract

Objective We investigated methotrexate safety and the influence of dose on efficacy outcomes in combination with three different biologic treatments and with active conventional treatment (ACT) in early rheumatoid arthritis (RA).Methods This post hoc analysis included 812 treatment-naive patients with early RA who were randomized (1:1:1:1) in the NORD-STAR trial to receive methotrexate in combination with ACT, certolizumab-pegol, abatacept, or tocilizumab. Methotrexate safety, doses, and dose effects on Clinical Disease Activity Index (CDAI) remission were assessed after 24 weeks of treatment.Results Compared with ACT, the prevalence of methotrexate-associated side effects was higher when methotrexate was combined with tocilizumab (hazard ratio [HR] 1.48, 95% confidence interval [CI] 1.20-1.84) but not with certolizumab-pegol (HR 0.99, 95% CI 0.79-1.23) or with abatacept (HR 0.93, 95% CI 0.75-1.16). With ACT as the reference, the methotrexate dose was significantly lower when used in combination with tocilizumab (beta -4.65, 95% CI -5.83 to -3.46; P < 0.001) or abatacept (beta -1.15, 95% CI -2.27 to -0.03; P = 0.04), and it was numerically lower in combination with certolizumab-pegol (beta -1.07, 95% CI -2.21 to 0.07; P = 0.07). Methotrexate dose reductions were not associated with decreased CDAI remission rates within any of the treatment combinations.Conclusion Methotrexate was generally well tolerated in combination therapies, but adverse events were a limiting factor in receiving the target dose of 25 mg/wk, and these were more frequent in combination with tocilizumab versus ACT. On the other hand, methotrexate dose reductions were not associated with decreased CDAI remission rates within any of the four treatment combinations at 24 weeks. imageConclusion Methotrexate was generally well tolerated in combination therapies, but adverse events were a limiting factor in receiving the target dose of 25 mg/wk, and these were more frequent in combination with tocilizumab versus ACT. On the other hand, methotrexate dose reductions were not associated with decreased CDAI remission rates within any of the four treatment combinations at 24 weeks. image

Data Provider: Clarivate

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+